表皮水疱症(EB)の市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Epidermolysis Bullosa (EB)—Market Insights, Epidemiology, and Market Forecast—2028
◆商品コード:DATA00109010
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:186
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥712,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,137,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Epidermolysis Bullosa (EB)—Market Insights, Epidemiology, and Market Forecast—2028
DelveInsight’s ‘Epidermolysis Bullosa (EB)—Market Insights, Epidemiology, and Market Forecast—2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of EB in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae. Epidermolysis bullosa usually is diagnosed in babies and children, but milder types can develop later in adulthood.

EB may be inherited in either a dominant or recessive form. In dominant EB, one parent usually carries the gene and is affected by the condition themselves, while the birth of a child suffering from the recessive form is usually totally unexpected since both parents can carry the EB gene without displaying the condition themselves. In dominant EB, there is a 50% chance of passing the disorder to children: in recessive EB the chance is 25%.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028

Epidermolysis Bullosa (EB)—Disease Understanding and Treatment Algorithm
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB.

There are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (epidermolytic), junctional EB (lucidolytic), dystrophic EB (dermolytic), and Kindler syndrome (mixed levels of blistering). Apart from this when EB also occurs due to any defect in the immune system it is called epidermolysis bullosa acquisita (EBA).

Epidermolysis Bullosa (EB) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM, Total Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM, and Type-specific Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM) scenario of Epidermolysis Bullosa (EB) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to DelveInsight, the total diagnosed cases of Epidermolysis Bullosa (EB) were found out to be 39,433 in 2017, in the 7MM. The number of Epidermolysis Bullosa (EB) cases in the 7MM is expected to increase during the study period of 2017–2028.

Epidermolysis Bullosa (EB) Drug Chapters
There is currently no cure for EB and treatments focus on preventing blisters or managing the wounds caused by the condition. There are different types of EB that are associated with blisters forming in different locations on the body and that vary in severity. Different treatments are used depending on the type of epidermolysis bullosa.

There are no EB-specific medications. Depending on the severity of the condition, doctors may recommend over-the-counter pain medication or may prescribe stronger painkillers, such as morphine, if needed. If the patient is experiencing chronic pain, then medicines such as amitriptyline, gabapentin or pregabalin may be prescribed. If a wound becomes infected, it may be treated with antibiotics. These can be applied as a topical lotion, a soaking solution, or taken as an oral tablet. Anti-inflammatory drugs such as corticosteroids may be prescribed to reduce pain from swallowing, making it easier to eat. With systemic corticosteroids, steroid-sparing agents, including colchicine, diaminodiphenyl sulfone (DDS, dapsone), methotrexate (MTX), azathioprine (AZA), cyclosporine (CSA), mycophenolate mofetil (MMF), and cyclophosphamide (CPA), have been reported in the treatment of EBA. Other therapeutic options, including high-dose intravenous Immunoglobulin (IVIG), rituximab (RTX), plasmapheresis and immune adsorption (IA), and extracorporeal photochemotherapy (ECP) also have been reported.

Epidermolysis Bullosa (EB) Market Outlook
The market size of Epidermolysis Bullosa (EB) in seven major markets (7MM) is estimated to be USD 2,296.31 million in 2017. The United States accounts for the highest market size of Epidermolysis Bullosa, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain and the United Kingdom), and Japan. Among the EU5 countries, the UK had the highest market size with USD 195.25 million in 2017, while Spain had the lowest market size of Epidermolysis Bullosa with USD 35.99 million in 2017.

Epidermolysis Bullosa (EB) Drugs Uptake
With the launch of emerging therapies that includes FCX-007 (Fibrocell Technologies), CCP-020 (Castle Creek Pharmaceuticals), RGN-137 (RegeneRx); AP-101 (Amryt Pharma), EB-101 (Abeona Therapeutics), KB103 (Krystal Biotech), and Ex-vivo expanded autologous with a COL7A1-encoding retroviral vector and LAMB3 encoding gene therapy (Holostem Terapie Avanzate), the market of EB is anticipated to change during the forecasted period (2019–2028).

Epidermolysis Bullosa (EB) Report Insights
• Patient Population by total diagnosed cases
• Type-specific diagnosed population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Epidermolysis Bullosa (EB) Report Key Strengths
• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Epidermolysis Bullosa (EB) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving EB market
• Organize sales and marketing efforts by identifying the best opportunities for EB market
• To understand the future market competition in the EB market.
Epidermolysis Bullosa (EB)—Market Insights, Epidemiology, and Market Forecast—2028

DelveInsight’s ‘Epidermolysis Bullosa (EB)—Market Insights, Epidemiology, and Market Forecast—2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of EB in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae. Epidermolysis bullosa usually is diagnosed in babies and children, but milder types can develop later in adulthood.

EB may be inherited in either a dominant or recessive form. In dominant EB, one parent usually carries the gene and is affected by the condition themselves, while the birth of a child suffering from the recessive form is usually totally unexpected since both parents can carry the EB gene without displaying the condition themselves. In dominant EB, there is a 50% chance of passing the disorder to children: in recessive EB the chance is 25%.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028

Epidermolysis Bullosa (EB)—Disease Understanding and Treatment Algorithm
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB.

There are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (epidermolytic), junctional EB (lucidolytic), dystrophic EB (dermolytic), and Kindler syndrome (mixed levels of blistering). Apart from this when EB also occurs due to any defect in the immune system it is called epidermolysis bullosa acquisita (EBA).

Epidermolysis Bullosa (EB) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM, Total Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM, and Type-specific Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM) scenario of Epidermolysis Bullosa (EB) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to DelveInsight, the total diagnosed cases of Epidermolysis Bullosa (EB) were found out to be 39,433 in 2017, in the 7MM. The number of Epidermolysis Bullosa (EB) cases in the 7MM is expected to increase during the study period of 2017–2028.

Epidermolysis Bullosa (EB) Drug Chapters
There is currently no cure for EB and treatments focus on preventing blisters or managing the wounds caused by the condition. There are different types of EB that are associated with blisters forming in different locations on the body and that vary in severity. Different treatments are used depending on the type of epidermolysis bullosa.

There are no EB-specific medications. Depending on the severity of the condition, doctors may recommend over-the-counter pain medication or may prescribe stronger painkillers, such as morphine, if needed. If the patient is experiencing chronic pain, then medicines such as amitriptyline, gabapentin or pregabalin may be prescribed. If a wound becomes infected, it may be treated with antibiotics. These can be applied as a topical lotion, a soaking solution, or taken as an oral tablet. Anti-inflammatory drugs such as corticosteroids may be prescribed to reduce pain from swallowing, making it easier to eat. With systemic corticosteroids, steroid-sparing agents, including colchicine, diaminodiphenyl sulfone (DDS, dapsone), methotrexate (MTX), azathioprine (AZA), cyclosporine (CSA), mycophenolate mofetil (MMF), and cyclophosphamide (CPA), have been reported in the treatment of EBA. Other therapeutic options, including high-dose intravenous Immunoglobulin (IVIG), rituximab (RTX), plasmapheresis and immune adsorption (IA), and extracorporeal photochemotherapy (ECP) also have been reported.

Epidermolysis Bullosa (EB) Market Outlook
The market size of Epidermolysis Bullosa (EB) in seven major markets (7MM) is estimated to be USD 2,296.31 million in 2017. The United States accounts for the highest market size of Epidermolysis Bullosa, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain and the United Kingdom), and Japan. Among the EU5 countries, the UK had the highest market size with USD 195.25 million in 2017, while Spain had the lowest market size of Epidermolysis Bullosa with USD 35.99 million in 2017.

Epidermolysis Bullosa (EB) Drugs Uptake
With the launch of emerging therapies that includes FCX-007 (Fibrocell Technologies), CCP-020 (Castle Creek Pharmaceuticals), RGN-137 (RegeneRx); AP-101 (Amryt Pharma), EB-101 (Abeona Therapeutics), KB103 (Krystal Biotech), and Ex-vivo expanded autologous with a COL7A1-encoding retroviral vector and LAMB3 encoding gene therapy (Holostem Terapie Avanzate), the market of EB is anticipated to change during the forecasted period (2019–2028).

Epidermolysis Bullosa (EB) Report Insights
• Patient Population by total diagnosed cases
• Type-specific diagnosed population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Epidermolysis Bullosa (EB) Report Key Strengths
• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Epidermolysis Bullosa (EB) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving EB market
• Organize sales and marketing efforts by identifying the best opportunities for EB market
• To understand the future market competition in the EB market.

【レポートの目次】

1. Key Insights
2. Epidermolysis Bullosa (EB) Market Overview at a Glance
2.1. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2017
2.2. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2028
3. Epidermolysis Bullosa (EB): Disease Background and Overview
3.1. Introduction
3.2. Causes of Epidermolysis Bullosa
3.3. Signs and Symptoms of Epidermolysis Bullosa
3.4. Classification of Epidermolysis Bullosa
3.5. Pathophysiology of Epidermolysis Bullosa
3.6. Genetic Bases of Epidermolysis Bullosa
3.7. Diagnosis of Epidermolysis Bullosa
3.8. Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa
4.3. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa
4.4. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa
5. Country Wise-Epidemiology of Epidermolysis Bullosa
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States
5.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States
5.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Epidermolysis Bullosa in Germany
5.2.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in Germany
5.2.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Epidermolysis Bullosa in France
5.2.2.3. Diagnosed Prevalence of Epidermolysis Bullosa in France
5.2.2.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Italy
5.2.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Italy
5.2.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Epidermolysis Bullosa in Spain
5.2.4.3. Diagnosed Prevalence of Epidermolysis Bullosa in Spain
5.2.4.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom
5.2.5.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
5.2.5.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Japan
5.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Japan
5.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan
6. Treatment and Management of Epidermolysis Bullosa (EB)
6.1. Skin and Wound Management
6.2. General Management Principles
6.3. Special Considerations
6.4. Management of Chronic wounds in EB
6.5. Pain care for patients with epidermolysis bullosa: best care practice guidelines
7. Unmet Needs
8. Emerging Drugs
8.1. Key Cross Competition
8.2. AP-101: Amryt Pharma
8.2.1. Prouduct Description
8.2.2. Other Development Activities
8.2.3. Clinical Development
8.2.4. Clinical Trials Information
8.2.5. Safety and Efficacy
8.2.6. Product Profile
8.3. EB-101: Abeona Therapeutics
8.3.1. Product Description
8.3.2. Other Development Activities
8.3.3. Clinical Development
8.3.4. Clinical Trials Information
8.3.5. Safety and Efficacy
8.3.6. Product Profile
8.4. CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
8.4.1. Product Description
8.4.2. Other Development Activities
8.4.3. Clinical Development
8.4.4. Clinical Trials Information
8.4.5. Safety and Efficacy
8.4.6. Product Profile
8.5. RGN-137: RegeneRx
8.5.1. Product Description
8.5.2. Other Development Activities
8.5.3. Clinical Development
8.5.4. Clinical Trials Information
8.5.5. Safety and Efficacy
8.5.6. Product Profile
8.6. KB103 (Bercolagene Telserpavec): Krystal Biotech
8.6.1. Product Description
8.6.2. Other Development Activities
8.6.3. Clinical Development
8.6.4. Clinical Trials Information
8.6.5. Safety and Efficacy
8.6.6. Product Profile
8.7. FCX-007: Fibrocell Technologies
8.7.1. Product Description
8.7.2. Other Development Activities
8.7.3. Clinical Development
8.7.4. Clinical Trials Information
8.7.5. Safety and Efficacy
8.7.6. Product Profile
8.8. Allo-APZ2-EB: RHEACELL GmbH
8.8.1. Product Description
8.8.2. Other Development Activities
8.8.3. Clinical Development
8.8.4. Clinical Trials Information
8.8.5. Product Profile
8.9. COL7 and LAMB3 gene therapy: Holostem Terapie Avanzate
8.9.1. Product Description
8.9.2. Other Development Activities
8.9.3. Clinical Development
8.9.4. Clinical Trials Information
8.9.5. Safety and Efficacy
8.9.6. Product Profile
8.10. HMGB1 peptides: Stemrim
8.10.1. Product Description
8.10.2. Other Development Activities
8.10.3. Product Profile
8.11. Failed Therapies for Epidermolysis Bullosa (EB)
8.12. JR-031: JCR Pharmaceuticals
8.12.1. Product Description
8.12.2. Other Development Activities
8.12.3. Clinical Development
8.12.4. Clinical Trials Information
8.12.5. Product Profile
8.13. Zorblisa: Amicus Therapeutics
8.13.1. Product Description
8.13.2. Other Development Activities
8.13.3. Clinical Development
8.13.4. Clinical Trials Information
8.13.5. Safety and Efficacy
8.13.6. Product Profile
9. Epidermolysis Bullosa: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Epidermolysis Bullosa in the 7MM
9.3. Market Size of Epidermolysis Bullosa by Therapies in the 7MM
10. Market Outlook: The United States
10.1. United States Market Size
10.1.1. The total Market size of Epidermolysis Bullosa
10.1.2. Market Size of Epidermolysis Bullosa by Therapies in the United States
11. Market Outlook: Europe
11.1. Germany
11.1.1. Total Market size of Epidermolysis Bullosa
11.1.2. Market Size of Epidermolysis Bullosa by Therapies in Germany
11.2. France
11.2.1. Total Market size of Epidermolysis Bullosa
11.2.2. Market Size of Epidermolysis Bullosa by Therapies in France
11.3. Italy
11.3.1. Total Market size of Epidermolysis Bullosa
11.3.2. Market Size of Epidermolysis Bullosa by Therapies in Italy
11.4. Spain
11.4.1. Total Market size of Epidermolysis Bullosa
11.4.2. Market Size of Epidermolysis Bullosa by Therapies in Spain
11.5. United Kingdom
11.5.1. Total Market size of Epidermolysis Bullosa
11.5.2. Market Size of Epidermolysis Bullosa by Therapies in the United Kingdom
12. Market Outlook: Japan
12.1. Total Market size of Epidermolysis Bullosa
12.2. Market Size of Epidermolysis Bullosa by Therapies in Japan
13. Market Drivers
14. Market Barriers
15. Appendix
15.1. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
Table 1 Classification of Epidermolysis Bullosa (EB)
Table 2 Level of Evidence
Table 3 Grades of recommendation made by the guideline panel
Table 4 Level of Evidence
Table 5 Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2017-2028)
Table 6 Diagnosed Prevalent Patient Population of Epidermolysis Bullosa in the 7MM (2017-2028)
Table 7 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa (2017-2028)
Table 8 Total Prevalent Population of Epidermolysis Bullosa in the United States (2017-2028)
Table 9 Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Table 10 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Table 11 Total Prevalent Population of Epidermolysis Bullosa in Germany (2017-2028)
Table 12 Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Table 13 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Table 14 Total Prevalent Population of Epidermolysis Bullosa in France (2017-2028)
Table 15 Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Table 16 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Table 17 Total Prevalent Population of Epidermolysis Bullosa in Italy (2017-2028)
Table 18 Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Table 19 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Table 20 Total Prevalent Population of Epidermolysis Bullosa in Spain (2017-2028)
Table 21 Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Table 22 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Table 23 Total Prevalent Population of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Table 24 Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Table 25 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Table 26 Total Prevalent Population of Epidermolysis Bullosa in Japan (2017-2028)
Table 27 Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Table 28 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Table 29 Recommended dressings for EBS localized and generalized
Table 30 Recommended dressings for patients with EBS-GS
Table 31 Recommended dressings for patients with JEB
Table 32 Recommended dressings for DEB
Table 33 Recommended dressings for patients with Kindler syndrome
Table 34 Recommended dressings for neonates with EB
Table 35 Care of the EB patient in the operating theatre
Table 36 Gastrostomy site management
Table 37 Tracheostomy care
Table 38 Recommendations for wound debridement in patients with EB
Table 39 Recommended antimicrobial treatments for infected and critically colonized wounds
Table 40 List of Few Emerging Drugs Analysis contd…
Table 41 List of Few Emerging Drugs Analysis
Table 42 AP-101 (Oleogel-S10), Clinical Trial Description, 2019
Table 43 EB-101, Clinical Trial Description, 2019
Table 44 Diacerein (CCP-020), Clinical Trial Description, 2019
Table 45 RGN-137, Clinical Trial Description, 2019
Table 46 KB103 (Bercolagene Telserpavec), Clinical Trial Description, 2019
Table 47 FCX-007, Clinical Trial Description, 2019
Table 48 Allo-APZ2-EB, Clinical Trial Description, 2019
Table 49 COL7 and LAMB3 gene therapy, Clinical Trial Description, 2019
Table 50 JR-031, Clinical Trial Description, 2019
Table 51 Zorblisa , Clinical Trial Description, 2019
Table 52 Market size of Epidermolysis Bullosa by Region in USD Million (2017–2028)
Table 53 Market Size of Epidermolysis Bullosa by Therapies in 7MM, in USD Million (2017–2028)
Table 54 United States Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 55 Market Size of Epidermolysis Bullosa by Therapies in the United States, in USD Million (2017–2028)
Table 56 Germany Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 57 Market Size of Epidermolysis Bullosa by Therapies in Germany, in USD Million (2017–2028)
Table 58 France Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 59 Market Size of Epidermolysis Bullosa by Therapies in France, in USD Million (2017–2028)
Table 60 Italy Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 61 Market Size of Epidermolysis Bullosa by Therapies in Italy, in USD Million (2017–2028)
Table 62 Spain Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 63 Market Size of Epidermolysis Bullosa by Therapies in Spain, in USD Million (2017–2028)
Table 64 United Kingdom Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 65 Market Size of Epidermolysis Bullosa by Therapies in the United Kingdom, in USD Million (2017–2028)
Table 66 Japan Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Table 67 Market Size of Epidermolysis Bullosa by Therapies in Japan, in USD Million (2017–2028)
Figure 1 Blister formation in Epidermolysis bullosa
Figure 2 Some common symptoms of Epidermolysis Bullosa
Figure 3 Types of Epidermolysis Bullosa
Figure 4 Keratin Proteins and EB Simplex
Figure 5 Pathology Outlines
Figure 6 The mechanism of epidermolysis bullosa
Figure 7 Pathogenesis of Epidermolysis Bullosa Acquisita
Figure 8 Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2017-2028)
Figure 9 Diagnosed Prevalence of Epidermolysis Bullosa in the 7MM (2017-2028)
Figure 10 7MM Type Specific Diagnosed Prevalence of Epidermolysis Bullosa (2017-2028)
Figure 11 Total Prevalent Cases of Epidermolysis Bullosa in the United States (2017-2028)
Figure 12 Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Figure 13 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
Figure 14 Total Prevalent Cases of Epidermolysis Bullosa in Germany (2017-2028)
Figure 15 Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Figure 16 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
Figure 17 Total Prevalent Cases of Epidermolysis Bullosa in France (2017-2028)
Figure 18 Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Figure 19 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
Figure 20 Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Figure 21 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
Figure 22 Total Prevalent Cases of Epidermolysis Bullosa in Spain (2017-2028)
Figure 23 Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Figure 24 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
Figure 25 Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Figure 26 Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Figure 27 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
Figure 28 Total Prevalent Cases of Epidermolysis Bullosa in Japan (2017-2028)
Figure 29 Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Figure 30 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Figure 31 Unmet Needs of EB
Figure 32 Drug Designation
Figure 33 Market size of Epidermolysis Bullosa by Region in USD Million (2017–2028)
Figure 34 Market Size of Epidermolysis Bullosa by Therapies in 7MM, in USD Million (2017–2028)
Figure 35 United States Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 36 Market Size of Epidermolysis Bullosa by Therapies in the United States in USD Million (2017-2028)
Figure 37 Germany Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 38 Market Size of Epidermolysis Bullosa by Therapies in Germany, in USD Million (2017-2028)
Figure 39 France Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 40 Market Size of Epidermolysis Bullosa by Therapies in France, in USD Million (2017-2028)
Figure 41 Italy Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 42 Market Size of Epidermolysis Bullosa by Therapies in Italy, in USD Million (2017-2028)
Figure 43 Spain Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 44 Market Size of Epidermolysis Bullosa by Therapies in Spain, in USD Million (2017-2028)
Figure 45 United Kingdom Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 46 Market Size of Epidermolysis Bullosa by Therapies in the UK, in USD Million (2017-2028)
Figure 47 Japan Market Size of Epidermolysis Bullosa in USD Million (2017-2028)
Figure 48 Market Size of Epidermolysis Bullosa by Therapies in Japan, in USD Million (2017-2028)
Figure 49 Market Drivers
Figure 50 Market Barriers



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[表皮水疱症(EB)の市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆